UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~April 4~~ May 13, 2008

FTS GROUP, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-24829	84-1416864
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)


300 State Street East, Suite 226, Oldsmar, Florida		34677
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (813) 749-8800

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 1 4.01 CHANGES ~~ENTRY~~IN ~~INTO~~REGISTRANT’S ACERTIFYING ~~MATERIAL DEFINITIVE AGREEMENT~~ACCOUNTANT.

~~On March~~Effective 19May 13, 2008, weour ~~entered~~Board ~~into~~of anDirectors ~~asset~~dismissed ~~purchase~~R.E. ~~agreement~~Bassie ~~with~~& ~~US Biodefense, Inc~~Co.~~, a~~ ~~Utah~~as ~~corporation, pursuant to which US Biodefense agreed to purchase 100% of~~our ~~the~~independent ~~common stock and assume full operating control of the directories and all funds received by our wholly-owned subsidiary, Elysium Internet, Inc~~accountant., R.E. aBassie ~~Florida corporation,~~& ~~beginning on the closing date which took place on April 4, 2008~~Co. ~~Upon~~ ~~closing~~performed ~~of this transaction, Elysium ceased to be~~ our ~~wholly-owned~~audits ~~subsidiary~~for ~~and~~the ~~became~~fiscal ayears ~~wholly-owned~~ended ~~subsidiary~~December ~~of US Biodefense. Mr. Scott Gallagher~~31, ~~our~~2006 ~~Chairman~~ and ~~Chief Executive Officer, is also the Chairman and Chief Executive Officer of US Biodefense~~2007.

~~Pursuant~~Except as reported in the Form to10-K for the ~~asset~~fiscal ~~purchase~~year ~~agreement~~ended December 31, in2007, ~~exchange~~and ~~for~~the aForm ~~wholly~~10-~~owned~~KSB/A ~~interest~~for inthe ~~Elysium,~~fiscal USyear ~~Biodefense~~ended ~~agreed~~December to31, ~~assume~~2006, ~~all~~each ~~liabilities~~of ~~related~~which tostated that "the ~~acquired~~Company has ~~assets~~suffered ~~and~~recurring ~~operation~~losses offrom ~~Elysium. In addition~~operations," USand ~~Biodefense~~that ~~agreed~~"[t]hese tofactors ~~issue us a~~raise ~~non-interest~~substantial ~~bearing~~doubt ~~promissory~~about ~~note~~the ~~for~~Company’s ~~$1,500,000~~ability ~~and~~to ~~upon~~continue ~~acceptance~~as bya ~~the~~going concern," ~~Utah~~the ~~Secretary~~reports of ~~State~~R.E. ofBassie a& ~~Certificate~~Co. ofon ~~Designation,~~our ~~issue~~financial usstatements ~~250~~for ~~shares~~the offiscal ayears ~~new~~ended ~~class~~December of31, US2007 ~~Biodefense~~and ~~preferred~~2006 ~~stock~~did ~~which~~not ~~will~~contain bean ~~convertible~~adverse ~~into~~opinion ~~60%~~or disclaimer of ~~the~~opinion, ~~issued~~ and ~~outstanding~~were ~~shares~~not ofmodified USas ~~Biodefense’s~~to ~~common~~uncertainty, ~~stock~~audit asscope, ~~of the~~or ~~date~~accounting ~~of our first conversion~~principals.

~~The~~In ~~promissory~~connection ~~note~~with isthe ~~payable~~audits byfor USthe ~~Biodefense~~past intwo 12fiscal ~~monthly~~years ~~installments~~and ofthrough the ~~$125~~termination date,~~000~~ ~~beginning~~there 30were ~~days~~no ~~after~~disagreements itwith ~~closes~~R.E. aBassie ~~financing~~& ~~of at least $250,000~~Co. ~~The~~, ~~entire~~whether ~~principal~~or ~~amount~~not isresolved, ~~due~~on toany usmatter noof ~~later~~accounting ~~than~~principals ~~January~~or 3practices, ~~2010. If US~~ ~~Biodefense~~financial ~~misses~~statement ~~a payment on the note~~disclosure, ~~and~~or ~~such~~auditing ~~payment~~scope isor ~~not~~procedure, ~~made~~which, ~~within~~if 7not ~~business~~resolved ~~days,~~to itR.E. ~~will~~Bassie be& inCo.’s ~~default under the note and upon receipt of our notice of default~~satisfaction, itwould ~~will~~ have 7caused ~~business days to cure such default~~R.E. ~~In the~~Bassie ~~event~~& ~~that~~Co. ~~the~~to ~~default~~make isreference ~~not~~to ~~cured within~~ the ~~prescribed~~subject ~~time~~matter ~~period, a default simple interest rate~~ of ~~15%~~the ~~per~~disagreement ~~annum will be applied to any amounts under the~~in ~~note~~connection ~~for~~with ~~which~~its ~~payment has not been made~~report.

InR.E. ~~addition,~~Bassie ~~upon~~& ~~our~~Co. ~~providing~~was USprovided ~~Biodefense with~~ a ~~notice~~copy of ~~default,~~the weforegoing ~~will have~~disclosures ~~the~~and ~~right~~was requested to ~~convert~~furnish ~~the~~a ~~defaulted~~letter ~~payments~~addressed onto the ~~note~~United ~~into~~States ~~shares~~Securities ~~of US~~and ~~Biodefense~~Exchange ~~common~~Commission ~~stock~~stating atwhether aor ~~conversion~~not ~~rate~~it ofagrees ~~70%~~with of the ~~closing~~above ~~price~~disclosures. As of ~~our common stock, as reported on~~ the ~~Over-the-Counter~~date ~~Bulletin~~of ~~Board,~~this ~~or OTCBB~~report, ~~for the~~we 5have ~~trading~~not ~~days~~received ~~prior to its receipt of~~ a ~~conversion~~copy ~~notice. We may also convert up to 15%~~ of the ~~outstanding balance of the note into shares of US~~letter ~~Biodefense~~pursuant ~~common~~to ~~stock~~that ~~any~~request. ~~time~~Upon ~~after~~receipt, 90we ~~days~~will ~~from~~file ~~the issuance date of the note at~~ a ~~conversion~~copy ~~rate~~ of ~~85% of~~ the ~~closing~~letter ~~price~~in ~~of its common stock, as~~an ~~reported~~amendment ~~on the OTCBB, for the 5 trading days prior~~ to ~~the~~this ~~receipt of a conversion notice~~report.

~~With respect~~On toMay ~~the~~13, ~~issuance~~2008, our Board of Directors engaged J. Crane & Company, P.C. as our ~~securities~~independent ~~described~~registered ~~above~~public accounting firm for the fiscal year ended December 31, we2008. ~~relied~~During the fiscal years ended December 31, 2007 and 2006 and through May 13, 2008, no one on ~~the~~our ~~Section~~behalf 4has consulted with J. Crane & Company regarding: (2i) ~~exemption~~the ~~from~~application of ~~securities~~accounting ~~registration~~principles ~~under~~to ~~the~~a ~~federal~~specified ~~securities~~transaction, either completed or ~~laws~~proposed; ~~for~~or ~~transactions~~the ~~not~~type ~~involving~~of ~~any~~audit ~~public~~opinion ~~offering.~~that Nomight ~~advertising~~be orrendered on our financial ~~general~~statements, ~~solicitation~~and neither a written report was ~~employed~~provided into ~~offering~~us ~~the~~nor ~~securities~~oral advice was provided that J. ~~The~~Crane ~~securities~~& Company concluded was an important factor ~~were~~considered ~~issued~~by tous ~~accredited~~in ~~investors.~~reaching ~~The~~a ~~securities~~decision ~~were~~as ~~offered~~to ~~for~~any ~~investment~~accounting, auditing or ~~purposes~~financial ~~only~~reporting ~~and~~issue; ~~not~~or ~~for~~(ii) any matter that was either the ~~purpose~~subject of ~~resale~~a disagreement or(as ~~distribution,~~that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable ~~transfer~~event ~~thereof~~(as ~~was~~that ~~appropriately~~term ~~restricted~~is bydefined usin Item 304(a)(1)(v) of Regulation S-K).

~~The~~This ~~foregoing~~report ~~description~~contains offorward-looking ~~the~~statements ~~asset~~that ~~purchase~~involve ~~agreement~~risks and ~~the promissory note~~uncertainties. ~~does~~You should not ~~purport~~place toundue bereliance ~~complete~~on ~~and~~these isforward-looking ~~qualified~~statements. inOur actual ~~its~~results ~~entirety~~could bydiffer ~~reference~~materially to from those anticipated in the forward-looking ~~full~~statements ~~text~~for ofmany reasons, including the ~~Asset~~risks ~~Purchase~~described ~~Agreement~~in our Form 10-K and other reports we file with the ~~Promissory~~Securities ~~Note~~and ~~due~~Exchange ~~January~~Commission. 3,Although ~~2010~~management believes the expectations reflected in the forward-looking statements are reasonable, ~~filed~~they relate only to events as ~~Exhibits~~of ~~10.1~~the date ~~and~~on 10which the statements are made.2 We do not intend to update any of the forward-looking statements after the date of this report ~~and~~to ~~incorporated~~conform these ~~herein~~statements to actual results or to changes in its expectations, except as required by ~~reference~~law.

This report contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including the risks described in our annual report on Form 10-K and other filings we make from time to time filed with the Securities and Exchange Commission. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made. We do not intend to update any of the forward-looking statements after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law.SIGNATURES

ITEM 9.01 EXHIBITS.

EXHIBIT NUMBER		DESCRIPTION
10.1		Asset Purchase Agreement between the Company and US Biodefense, Inc., dated March 19, 2008 (filed herewith).
10.2		Promissory Note due January 3, 2010, issued to the Company by US Biodefense, Inc. (filed herewith).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	FTS Group, Inc.	~~FTS Group, Inc.~~
	(Registrant)	~~(Registrant)~~
Date	April 10, 2008
Date May 19, 2008	/s/ Scott Gallagher
		/s/ Scott Gallagher
	Scott Gallagher
		(Signature)
	Chief Executive Officer
		Name: Scott Gallagher
		Title: Chief Executive Officer

Filing Compare · FTS GROUP, INC.